Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial.
Ørnbjerg LM, Østergaard M, Jensen T, Hørslev-Petersen K, Stengaard-Pedersen K, Junker P, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Dam MY, Hansen I, Lottenburger T, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun J, Hetland ML; OPERA Study Group; Slot O, Nielsen LK, Skjødt H, Majgaard O, Lorenzen T, Horn HC, Kowalski M, Johansen IL, Pedersen PM, Manilo N, Bliddal H. Ørnbjerg LM, et al. Among authors: majgaard o. Clin Rheumatol. 2017 Apr;36(4):781-789. doi: 10.1007/s10067-016-3489-1. Epub 2016 Dec 5. Clin Rheumatol. 2017. PMID: 27921185 Clinical Trial.
MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA).
Hetland ML, Ejbjerg B, Hørslev-Petersen K, Jacobsen S, Vestergaard A, Jurik AG, Stengaard-Pedersen K, Junker P, Lottenburger T, Hansen I, Andersen LS, Tarp U, Skjødt H, Pedersen JK, Majgaard O, Svendsen AJ, Ellingsen T, Lindegaard H, Christensen AF, Vallø J, Torfing T, Narvestad E, Thomsen HS, Ostergaard M; CIMESTRA study group. Hetland ML, et al. Among authors: majgaard o. Ann Rheum Dis. 2009 Mar;68(3):384-90. doi: 10.1136/ard.2008.088245. Epub 2008 Apr 3. Ann Rheum Dis. 2009. PMID: 18388160 Clinical Trial.
Differentiation between early rheumatoid arthritis patients and healthy persons by conventional and dynamic contrast-enhanced magnetic resonance imaging.
Axelsen MB, Ejbjerg BJ, Hetland ML, Skjødt H, Majgaard O, Lauridsen UB, Hørslev-Petersen K, Boesen M, Kubassova O, Bliddal H, Østergaard M. Axelsen MB, et al. Among authors: majgaard o. Scand J Rheumatol. 2014;43(2):109-18. doi: 10.3109/03009742.2013.824022. Epub 2013 Nov 6. Scand J Rheumatol. 2014. PMID: 24191910
Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondylarthritis treated with tumor necrosis factor α inhibitors: a study of radiographic progression, inflammation on magnetic resonance imaging, and circulating biomarkers of inflammation, angiogenesis, and cartilage and bone turnover.
Pedersen SJ, Sørensen IJ, Lambert RG, Hermann KG, Garnero P, Johansen JS, Madsen OR, Hansen A, Hansen MS, Thamsborg G, Andersen LS, Majgaard O, Loft AG, Erlendsson J, Asmussen KH, Jurik AG, Møller J, Hasselquist M, Mikkelsen D, Østergaard M. Pedersen SJ, et al. Among authors: majgaard o. Arthritis Rheum. 2011 Dec;63(12):3789-800. doi: 10.1002/art.30627. Arthritis Rheum. 2011. PMID: 22127697 Free article.
Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
Pedersen SJ, Sørensen IJ, Hermann KG, Madsen OR, Tvede N, Hansen MS, Thamsborg G, Andersen LS, Majgaard O, Loft AG, Erlendsson J, Asmussen K, Johansen JS, Jurik AG, Møller J, Hasselquist M, Mikkelsen D, Skjødt T, Hansen A, Ostergaard M. Pedersen SJ, et al. Among authors: majgaard o. Ann Rheum Dis. 2010 Jun;69(6):1065-71. doi: 10.1136/ard.2009.111187. Epub 2009 Sep 9. Ann Rheum Dis. 2010. PMID: 19740906
ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors.
Pedersen SJ, Sørensen IJ, Garnero P, Johansen JS, Madsen OR, Tvede N, Hansen MS, Thamsborg G, Andersen LS, Majgaard O, Loft AG, Erlendsson J, Asmussen K, Jurik AG, Møller J, Hasselquist M, Mikkelsen D, Skjødt T, Lambert R, Hansen A, Østergaard M. Pedersen SJ, et al. Among authors: majgaard o. Ann Rheum Dis. 2011 Aug;70(8):1375-81. doi: 10.1136/ard.2010.138883. Epub 2011 May 8. Ann Rheum Dis. 2011. PMID: 21551511 Clinical Trial.
Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA).
Hørslev-Petersen K, Hetland ML, Ørnbjerg LM, Junker P, Pødenphant J, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Dam MY, Hansen I, Lottenburger T, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun J, Johansen JS, Østergaard M, Stengaard-Pedersen K; OPERA Study-Group. Hørslev-Petersen K, et al. Ann Rheum Dis. 2016 Sep;75(9):1645-53. doi: 10.1136/annrheumdis-2015-208166. Epub 2015 Oct 21. Ann Rheum Dis. 2016. PMID: 26489704 Clinical Trial.
Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial.
Jensen TW, Hansen MS, Hørslev-Petersen K, Hyldstrup L, Abrahamsen B, Langdahl B, Zerahn B, Pødenphant J, Stengaard-Petersen K, Junker P, Østergaard M, Lottenburger T, Ellingsen T, Andersen LS, Hansen I, Skjødt H, Pedersen JK, Lauridsen UB, Svendsen AJ, Tarp U, Lindegaard H, Jurik AG, Vestergaard A, Hetland ML; Cimestra study group. Jensen TW, et al. Ann Rheum Dis. 2014 Jun;73(6):1123-9. doi: 10.1136/annrheumdis-2012-203171. Epub 2013 May 9. Ann Rheum Dis. 2014. PMID: 23661492 Clinical Trial.
Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
Hørslev-Petersen K, Hetland ML, Junker P, Pødenphant J, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Dam MY, Hansen I, Horn HC, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun J, Johansen JS, Østergaard M, Stengaard-Pedersen K; OPERA Study-Group. Hørslev-Petersen K, et al. Ann Rheum Dis. 2014 Apr;73(4):654-61. doi: 10.1136/annrheumdis-2012-202735. Epub 2013 Feb 23. Ann Rheum Dis. 2014. PMID: 23434570 Clinical Trial.
Short- and long-term efficacy of intra-articular injections with betamethasone as part of a treat-to-target strategy in early rheumatoid arthritis: impact of joint area, repeated injections, MRI findings, anti-CCP, IgM-RF and CRP.
Hetland ML, Østergaard M, Ejbjerg B, Jacobsen S, Stengaard-Pedersen K, Junker P, Lottenburger T, Hansen I, Andersen LS, Tarp U, Svendsen A, Pedersen JK, Skjødt H, Ellingsen T, Lindegaard H, Pødenphant J, Hørslev-Petersen K; CIMESTRA study group. Hetland ML, et al. Ann Rheum Dis. 2012 Jun;71(6):851-6. doi: 10.1136/annrheumdis-2011-200632. Epub 2012 Feb 1. Ann Rheum Dis. 2012. PMID: 22302316 Clinical Trial.
11 results